161 related articles for article (PubMed ID: 21115164)
1. Pheochromocytomas: the (pseudo)-hypoxia hypothesis.
Favier J; Gimenez-Roqueplo AP
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):957-68. PubMed ID: 21115164
[TBL] [Abstract][Full Text] [Related]
2. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
3. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
5. Genetics of pheochromocytomas and paragangliomas.
Opocher G; Schiavi F
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
[TBL] [Abstract][Full Text] [Related]
6. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
[TBL] [Abstract][Full Text] [Related]
7. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors.
Jochmanová I; Zelinka T; Widimský J; Pacak K
Physiol Res; 2014; 63(Suppl 2):S251-62. PubMed ID: 24908231
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
Pang Y; Yang C; Schovanek J; Wang H; Bullova P; Caisova V; Gupta G; Wolf KI; Semenza GL; Zhuang Z; Pacak K
Oncotarget; 2017 Apr; 8(14):22313-22324. PubMed ID: 28423608
[TBL] [Abstract][Full Text] [Related]
11. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas.
Dahia PL;
Ann N Y Acad Sci; 2006 Aug; 1073():208-20. PubMed ID: 17102089
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytoma and functional paraganglioma.
Roman S
Curr Opin Oncol; 2004 Jan; 16(1):8-12. PubMed ID: 14685086
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular progress in hereditary paraganglioma.
Baysal BE
J Med Genet; 2008 Nov; 45(11):689-94. PubMed ID: 18978332
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
[TBL] [Abstract][Full Text] [Related]
15. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas.
Merlo A; de Quiros SB; Secades P; Zambrano I; Balbín M; Astudillo A; Scola B; Arístegui M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2012 Nov; 97(11):E2194-200. PubMed ID: 22977270
[TBL] [Abstract][Full Text] [Related]
16. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
17. 15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma.
Mannelli M; Rapizzi E; Fucci R; Canu L; Ercolino T; Luconi M; Young WF
Endocr Relat Cancer; 2015 Aug; 22(4):T83-90. PubMed ID: 26113605
[TBL] [Abstract][Full Text] [Related]
18. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.
Richter S; Qin N; Pacak K; Eisenhofer G
Adv Pharmacol; 2013; 68():285-317. PubMed ID: 24054150
[TBL] [Abstract][Full Text] [Related]
19. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
20. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.
Opotowsky AR; Moko LE; Ginns J; Rosenbaum M; Greutmann M; Aboulhosn J; Hageman A; Kim Y; Deng LX; Grewal J; Zaidi AN; Almansoori G; Oechslin E; Earing M; Landzberg MJ; Singh MN; Wu F; Vaidya A
J Clin Endocrinol Metab; 2015 Apr; 100(4):1325-34. PubMed ID: 25581599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
